Clear cell renal cell carcinoma with heterotopic bone formation: A case report and literature review

Abstract

The phenomenon of heterotopic bone formation (osseous metaplasia) is defined as an abnormal ossification of non-skeletal tissues and does represent a rare occurrence in the renal cell carcinoma setting. We describe a case of a 40-year old man with bilateral renal cell carcinomas of the histological clear cell subtype, with the right-sided renal cell carcinoma demonstrating heterotopic bone formation, as well as the presence of intratumoral adipose tissue. The etiology of bone formation in a renal cell carcinoma is unclear, but possible explanations include a response to tissue ischemia and the expression of Bone Morphogenetic Protein 2. The detection of these rare morphologic variations is of paramount importance, not to be mistaken as sarcomatoid transformation and renal sinus fat invasion, which would advance the pathologic tumor stage and aggressiveness of the disease.

Keywords

Renal cell carcinoma / Clear cell / Heterotopic bone / Osseous metaplasia / Ossification

CONFLICTS OF INTEREST DISCLOSURE

The authors declare that they have no competing interest.

References

[1] American Cancer Society. Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society; 2018. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html

[2] Cribbs R, Ishaq M, Arnold M, et al. Renal cell carcinoma with massive osseous metaplasia and bone marrow elements. Ann Diagn Pathol. 1999; 3(5): 294-299. https://doi.org/10.1016/S1092-9134(99)80025-2

[3] Asghar AM, Ulhman MA, Dahmoush L, et al. Osseous metaplasia in mucinous tubular and spindle cell carcinoma of the kidney: a case of massive, bilateral tumors. Case Rep Urol. 2015; 465450. https://doi.org/10.1155/2015/465450

[4] Aird JJ, Nic An Riogh UA, Fleming S, et al. Papillary Renal Cell Carcinoma With Osteosarcomatous Heterologous Differentiation: A Case Report With Molecular Genetic Analysis and Review of the Literature. Int J Surg Pathol. 2017; 25(8): 745-750. PMid:28669254. https://doi.org/10.1177/1066896917716772

[5] Fukuoka T, Honda M, Namiki M, et al. Renal cell carcinoma with heterotopic bone formation. Case report and review of the Japanese literature. Urol Int. 1987; 42(6): 458-460.

[6] Hussain M, Ud Din N, Azam M, et al. mucinous tubular and spindle cell carcinoma of kidney: a clinicopathologic study of six cases. Indian J Pathol Microbiol. 2012; 55(4): 439-442. PMid:23455776. https://doi.org/10.4103/0377-4929.107776

[7] Jindal T, Jain N, Agarwal A. Type II papillary renal cell carcinoma with heterotrophic ossification: a case report. Ann R Coll Surg Engl. 2018; 100(3): e49-e50 PMid:29493352. https://doi.org/10.1308/rcsann.2017.0212

[8] Tanaka Y, Koie T, Hatakeyama S, et al. Chromophobe renal cell carcinoma with concomitant sarcomatoid transformation and osseous metaplasia:a case report. BMC Urology. 2013; 13: 72. Available from: http://www.biomedcentral.com/1471-2490/13/72

[9] Aron M, Aydin H, Sercia L, et al. Renal cell carcinoma with intratumoral fat and concomitant angiomyolipoma: potential pitfalls in staging and diagnosis. Am J Clin Pathol. 2010; 134(5): 807-812. PMid:20959665. https://doi.org/10.1309/AJCPO19JAPYRDTID

[10] Wang L, Park P, Zhang H, et al. BMP-2 inhibits tumor growth of human renal cell carcinoma and induces bone formation. Int J Cancer. 2012; 131(8): 1941-1950. PMid:22275155. https://doi.org/10.1002/ijc.27444

[11] Wang L, Park P, La Marca F, et al. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. J Cancer Res Clin Oncol. 2015; 141(6): 1013-1024. PMid:25431339. https://doi.org/10.1007/s00432-014-1883-0

[12] Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242 (4885): 1528-1534. https://doi.org/10.1126/science.3201241

[13] Yamasaki M, Nomura T, Mimata H, et al. Involvement of bone morphogenetic protein 2 in ossification of renal cell carcinoma. J Urol. 2004; 172(2): 475-476. PMid:15247706. https://doi.org/10.1097/01.ju.0000130509.34235.ef